On September 30, 2024, BlackRock, Inc., a Delaware-based investment management corporation, filed a Schedule 13G with the Securities and Exchange Commission (SEC), disclosing a 7.8% ownership stake in EyePoint Pharmaceuticals, Inc. This filing indicates that BlackRock now beneficially owns 4,155,158 shares of common stock in EyePoint Pharmaceuticals. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors to report their holdings. The document clarifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of EyePoint Pharmaceuticals. The address of EyePoint Pharmaceuticals' principal executive offices is listed as 480 Pleasant Street, Suite B300, Watertown, MA 02472-2468. The filing includes a list of subsidiaries under BlackRock, Inc. that may own 5% or more of the outstanding shares of the security class being reported.

On September 30, 2024, BlackRock, Inc., a Delaware-based investment management corporation, filed a Schedule 13G with the Securities and Exchange Commission (SEC), disclosing a 7.8% ownership stake in EyePoint Pharmaceuticals, Inc. This filing indicates that BlackRock now beneficially owns 4,155,158 shares of common stock in EyePoint Pharmaceuticals. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors to report their holdings. The document clarifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of EyePoint Pharmaceuticals. The address of EyePoint Pharmaceuticals' principal executive offices is listed as 480 Pleasant Street, Suite B300, Watertown, MA 02472-2468. The filing includes a list of subsidiaries under BlackRock, Inc. that may own 5% or more of the outstanding shares of the security class being reported.